Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.79 +0.22 (+1.25%)

Delayed Quote Updated: 12:10 PM EST, Nov 6, 2026 Add to My Watchlist

Price and Volume

Volume	788,239
Open	18.77
Bid (Size)	17.79 (300)
Ask (Size)	17.83 (300)
Prev. Close	17.57
Today's Range	17.52 - 18.77
52wk Range	14.68 - 24.68
Shares Outstanding	93,148,652
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Sarepta (SRPT) Q3 2026 Earnings Call Transcript ↗

Today 11:14 EST

Gene therapy demand stabilizes while siRNA readouts and FDA talks loom ahead.

Via The Motley Fool

Sarepta Therapeutics Q3 Earnings Call Highlights ↗

Today 4:14 EST

Sarepta Therapeutics (NASDAQ:SRPT) raised the low end of its 2026 product revenue forecast after reporting stable demand indicators for Duchenne muscular dystrophy gene therapy ELEVIDYS and continued...

Via MarketBeat

Performance

52-Week Range 27.9% below 52-week high

17.79

14.6852W Low 24.6852W High

1 Week 8.8% below 1-week high

17.441W Low 19.501W High

Sarepta Therapeutics, Inc. - Common Stock (SRPT) traded between $14.68 and $24.68 over the past 52 weeks and last traded at $17.79, 27.9% below its 52-week high. Over the past week it ranged between $17.44 and $19.50.

Past 12 Months

-4.5%

+2.8%

+6.0%

-14.5%

-16.5%

-4.7%

1W -$0.83

1M +$0.48

3M +$1.01

6M -$3.01

YTD -$3.52

1Y -$0.88

SRPT was -4.7% over the past year, -14.5% over six months, -16.5% year to date, -4.5% in the last week.

12 Months vs Market

SRPT

-4.7%

DIA

+8.8%

SPY

+9.1%

QQQ

+5.7%

IWM

+11.9%

Over the past 12 months SRPT returned -4.7% versus DIA (Dow) +8.8%, SPY (S&P 500) +9.1%, QQQ (Nasdaq 100) +5.7% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 0.28× 3-mo avg

Today 788,239 3-mo avg 2.8M

1.4M

2.6M

2.8M

3.1M

YTD

3.0M

3.1M

SRPT most recently traded 788,239 shares against a 3-month average daily volume of 2.8M.

More News

Sarepta Therapeutics (NASDAQ:SRPT) Q3 2026 Beat Fails to Lift Shares as Pipeline Readouts Loom ↗

November 05, 2026

Via Chartmill

Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments

November 05, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics (NASDAQ:SRPT) Surges on Q2 Earnings Beat and Narrowed Outlook ↗

August 05, 2026

Via Chartmill

Sarepta Therapeutics to Present at Upcoming Investor Conferences

October 26, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

October 22, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

October 14, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

October 05, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 30, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

September 30, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

September 25, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

September 24, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near ↗

September 15, 2026

Via MarketBeat

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

September 08, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

August 31, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

August 24, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Sarepta (SRPT) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Via The Motley Fool

Sarepta Therapeutics Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

August 05, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 29, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

July 27, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

July 22, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

2 Beaten-Down Stocks That Still Aren't Worth Buying ↗

July 11, 2026

Via The Motley Fool

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 30, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?

Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?

Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?

The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market

What is the current price of Sarepta Therapeutics, Inc. - Common Stock?

The current price of Sarepta Therapeutics, Inc. - Common Stock is 17.79

When was Sarepta Therapeutics, Inc. - Common Stock last traded?

The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 11/06/26 12:10 PM ET

What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?

The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 1.66B

How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?

Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.